Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

on. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.

    Conclusion

    - In virtually all patients with prostate cancer, tumor cells appear to
      express LHRH receptors;
    - Even tumors persisting or relapsing after castration or prolonged
      hormonal treatment with LHRH agonists retain the expression of LHRH
      receptors;
    - The continued expression of these receptors supports the concept of
      targeting prostatic LHRH receptors to deliver cytotoxic therapy based
      on LHRH analogs, such as AEZS-108.

A copy of the abstract is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic virus products for cancer, together ... enrollment has been initiated and the first patient ... trial called TRAVERSE.  The trial is evaluating the ...
... BRISBANE, Calif., Nov. 3, 2011 InterMune, Inc. (NASDAQ: ... for the third quarter and nine months ended September ... clinical development activities, including the launch of Esbriet® (pirfenidone) ... Executive Officer and President of InterMune said, "The third ...
... 3, 2011 Reportlinker.com announces that a new ... Global Biochip Markets: Microarrays ... INTRODUCTION  ... BCC,s goal for this study was to determine ...
Cached Biology Technology:Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 3Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 4Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 5Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... BIRMINGHAM, Ala. The U.S. Department of Energy (DOE) ... of Alabama at Birmingham (UAB) School of Engineering on ... the capture and permanent safe storage, or sequestration, of ... Southern Company, the parent company of Alabama Power. ...
... is publishing a special issue "Beyond the Origin: Charles ... of Species which was published 150 years ago in November ... Dr. Ulrich Kutschera, professor of plant physiology and evolutionary biology ... this special issue are available free of charge until 30 ...
... brilliance of butterfly wings has inspired a 3.2m, three-year ... fields of security, energy and the environment. The University ... signed a collaborative contract to develop new technologies based ... next three years a team of physicists from the ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: